ArticleJournal of gastrointestinal oncology2025
Effects of anlotinib combined with camrelizumab and chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma on tumor immune microenvironment.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04471480 (Paclitaxel and Carboplatin Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Esophageal Cancer), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Paclitaxel and Carboplatin Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Esophageal Cancer(ESCC)
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) presents significant therapeutic challenges due to limited treatment options. While immune checkpoint inhibitors (ICIs) combined with chemotherapy have demonstrated efficacy, variable response rates underscore the necessity for enhanced therapeutic approaches. Anlotinib, a multi-target tyrosine kinase inhibitor, has shown synergistic effects with ICIs in clinical practice. However, its influence on the tumor immune microenvironment (TIME) in ESCC requires further elucidation. This study aimed to investigate anlotinib's effects on the TIME. Methods: In our phase II trial (NCT04471480), we analyzed 8 advanced ESCC patients who achieved operability following treatment with anlotinib, camrelizumab, and chemotherapy (TCAC group). A control group (TCC group) comprised 8 patients from a separate neoadjuvant trial who received identical treatment, excluding anlotinib. Tumor-infiltrating immune cell populations (CD4 Results: Baseline immune cell profiles showed no significant intergroup differences. Post-treatment analysis revealed the TCAC group had significantly elevated CD8 Conclusions: The combination of anlotinib with camrelizumab and chemotherapy appears to modify the ESCC immune microenvironment by promoting cytotoxic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.